Stereotaxis Operating Income 2010-2024 | STXS
Stereotaxis operating income from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
| Stereotaxis Annual Operating Income (Millions of US $) |
|
|---|---|
| 2024 | $-25 |
| 2023 | $-22 |
| 2022 | $-19 |
| 2021 | $-13 |
| 2020 | $-7 |
| 2019 | $-5 |
| 2018 | $-2 |
| 2017 | $-6 |
| 2016 | $-6 |
| 2015 | $-5 |
| 2014 | $-5 |
| 2013 | $-9 |
| 2012 | $-11 |
| 2011 | $-32 |
| 2010 | $-19 |
| 2009 | $-24 |
| Stereotaxis Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-8 |
| 2024-09-30 | $-6 |
| 2024-06-30 | $-6 |
| 2024-03-31 | $-5 |
| 2023-12-31 | $-5 |
| 2023-09-30 | $-6 |
| 2023-06-30 | $-5 |
| 2023-03-31 | $-6 |
| 2022-12-31 | $-4 |
| 2022-09-30 | $-5 |
| 2022-06-30 | $-5 |
| 2022-03-31 | $-4 |
| 2021-12-31 | $-3 |
| 2021-09-30 | $-5 |
| 2021-06-30 | $-3 |
| 2021-03-31 | $-2 |
| 2020-12-31 | $-1 |
| 2020-09-30 | $-2 |
| 2020-06-30 | $-2 |
| 2020-03-31 | $-2 |
| 2019-12-31 | $-1 |
| 2019-09-30 | $0 |
| 2019-06-30 | $-1 |
| 2019-03-31 | $-2 |
| 2018-12-31 | $-1 |
| 2018-09-30 | $0 |
| 2018-06-30 | $-1 |
| 2018-03-31 | $-1 |
| 2017-12-31 | $-4 |
| 2017-09-30 | $0 |
| 2017-06-30 | $0 |
| 2017-03-31 | $-2 |
| 2016-12-31 | $-2 |
| 2016-09-30 | $-1 |
| 2016-06-30 | $-2 |
| 2016-03-31 | $-1 |
| 2015-12-31 | $-1 |
| 2015-09-30 | $-1 |
| 2015-06-30 | $-2 |
| 2015-03-31 | $-1 |
| 2014-12-31 | $0 |
| 2014-09-30 | $-1 |
| 2014-06-30 | $-2 |
| 2014-03-31 | $-2 |
| 2013-12-31 | $-2 |
| 2013-09-30 | $-1 |
| 2013-06-30 | $-2 |
| 2013-03-31 | $-4 |
| 2012-12-31 | $-1 |
| 2012-09-30 | $-1 |
| 2012-06-30 | $-5 |
| 2012-03-31 | $-4 |
| 2011-12-31 | $-5 |
| 2011-09-30 | $-9 |
| 2011-06-30 | $-10 |
| 2011-03-31 | $-9 |
| 2010-12-31 | $-3 |
| 2010-09-30 | $-4 |
| 2010-06-30 | $-6 |
| 2010-03-31 | $-6 |
| 2009-12-31 | $-6 |
| 2009-09-30 | $-4 |
| 2009-06-30 | $-7 |
| 2009-03-31 | $-7 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.174B | $0.027B |
| Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters, guidewires and stent delivery devices through the blood vessels and chambers of the heart to treatment sites. | |||